Pfizer to buy Seagen for $43B to enhance reach of cancer drugs
Drugmaker seeks out new revenue sources as expiration of patents protecting drugs like Ibrance from competition nears.
Drugmaker seeks out new revenue sources as expiration of patents protecting drugs like Ibrance from competition nears.